Literature DB >> 27075462

IL-23/IL-17 axis in spondyloarthritis-bench to bedside.

Siba P Raychaudhuri1,2,3, Smriti K Raychaudhuri4,5.   

Abstract

Cytokines play a critical role in the pathogenesis of psoriatic arthritis, ankylosing spondylitis, and other types of spondyloarthritis (SpA). Besides IFN-γ and TNF-α; IL-23/IL-17 cytokines play a dominant role in the inflammatory and proliferative cascades of SpA. Recently, in a series of elegant experiments using mouse models and human tissues, it has been demonstrated that IL-23-induced Th17 cytokines (IL-17 and IL-22) can contribute to following pathologic events associated with SpA: development of psoriatic plaque, pannus formation in the joint, joint erosion, and new bone formation. In this review article, we have discussed the contributing role of the IL-23/IL-17 cytokine axis in the pathogenesis of PsA and AS. IL-23/IL-17-targeted therapies are very promising for SpA, and we have provided an outline about usefulness of these new groups of biologics in SpA.

Entities:  

Keywords:  Ankylosing spoindylitis; IL-17; IL-23; Psoriatic arthritis; Spondyloarthritis; Th17 Cell

Mesh:

Substances:

Year:  2016        PMID: 27075462     DOI: 10.1007/s10067-016-3263-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  48 in total

1.  Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis.

Authors:  Heiner Appel; Maren Kuhne; Simone Spiekermann; Harald Ebhardt; Zarko Grozdanovic; Dorothee Köhler; Marc Dreimann; Axel Hempfing; Martin Rudwaleit; Harald Stein; Peter Metz-Stavenhagen; Joachim Sieper; Christoph Loddenkemper
Journal:  Arthritis Rheum       Date:  2006-09

Review 2.  Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis.

Authors:  Smriti K Raychaudhuri; Ankit Saxena; Siba P Raychaudhuri
Journal:  Clin Rheumatol       Date:  2015-05-05       Impact factor: 2.980

3.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.

Authors:  Ivaylo I Ivanov; Brent S McKenzie; Liang Zhou; Carlos E Tadokoro; Alice Lepelley; Juan J Lafaille; Daniel J Cua; Dan R Littman
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

4.  IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding.

Authors:  S G Hymowitz; E H Filvaroff; J P Yin; J Lee; L Cai; P Risser; M Maruoka; W Mao; J Foster; R F Kelley; G Pan; A L Gurney; A M de Vos; M A Starovasnik
Journal:  EMBO J       Date:  2001-10-01       Impact factor: 11.598

Review 5.  Recent advances in IL-22 biology.

Authors:  Lauren A Zenewicz; Richard A Flavell
Journal:  Int Immunol       Date:  2011-03       Impact factor: 4.823

6.  Molecular characterization of the human interleukin (IL)-17 receptor.

Authors:  Z Yao; M K Spriggs; J M Derry; L Strockbine; L S Park; T VandenBos; J D Zappone; S L Painter; R J Armitage
Journal:  Cytokine       Date:  1997-11       Impact factor: 3.861

7.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Authors:  Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

8.  Secukinumab in plaque psoriasis--results of two phase 3 trials.

Authors:  Richard G Langley; Boni E Elewski; Mark Lebwohl; Kristian Reich; Christopher E M Griffiths; Kim Papp; Lluís Puig; Hidemi Nakagawa; Lynda Spelman; Bárður Sigurgeirsson; Enrique Rivas; Tsen-Fang Tsai; Norman Wasel; Stephen Tyring; Thomas Salko; Isabelle Hampele; Marianne Notter; Alexander Karpov; Silvia Helou; Charis Papavassilis
Journal:  N Engl J Med       Date:  2014-07-09       Impact factor: 91.245

9.  Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.

Authors:  Christopher T Ritchlin; Sally A Haas-Smith; Ping Li; David G Hicks; Edward M Schwarz
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

10.  Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci.

Authors:  John D Reveille; Anne-Marie Sims; Patrick Danoy; David M Evans; Paul Leo; Jennifer J Pointon; Rui Jin; Xiaodong Zhou; Linda A Bradbury; Louise H Appleton; John C Davis; Laura Diekman; Tracey Doan; Alison Dowling; Ran Duan; Emma L Duncan; Claire Farrar; Johanna Hadler; David Harvey; Tugce Karaderi; Rebecca Mogg; Emma Pomeroy; Karena Pryce; Jacqueline Taylor; Laurie Savage; Panos Deloukas; Vasudev Kumanduri; Leena Peltonen; Sue M Ring; Pamela Whittaker; Evgeny Glazov; Gethin P Thomas; Walter P Maksymowych; Robert D Inman; Michael M Ward; Millicent A Stone; Michael H Weisman; B Paul Wordsworth; Matthew A Brown
Journal:  Nat Genet       Date:  2010-01-10       Impact factor: 38.330

View more
  16 in total

Review 1.  Secukinumab: a promising therapeutic option in spondyloarthritis.

Authors:  Hernan Maldonado-Ficco; Rodolfo Perez-Alamino; José A Maldonado-Cocco
Journal:  Clin Rheumatol       Date:  2016-07-20       Impact factor: 2.980

Review 2.  Stress proteins in the pathogenesis of spondyloarthritis.

Authors:  José Pablo Romero-López; María Lilia Domínguez-López; Rubén Burgos-Vargas; Ethel García-Latorre
Journal:  Rheumatol Int       Date:  2018-05-31       Impact factor: 2.631

3.  Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.

Authors:  Maria Sole Chimenti; Augusta Ortolan; Mariagrazia Lorenzin; Paola Triggianese; Marina Talamonti; Luisa Costa; Francesco Caso; Marta Favero; Miriam Teoli; Marco Galluzzo; Raffaele Scarpa; Leonardo Punzi; Roberto Perricone; Roberta Ramonda
Journal:  Clin Rheumatol       Date:  2018-01-04       Impact factor: 2.980

4.  Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis.

Authors:  Lu Yang; Melania H Fanok; Aranzazu Mediero-Munoz; Laura K Fogli; Carmen Corciulo; Shahla Abdollahi; Bruce N Cronstein; Jose U Scher; Sergei B Koralov
Journal:  Arthritis Rheumatol       Date:  2018-04-18       Impact factor: 10.995

Review 5.  A systems approach to renal inflammation in SLE.

Authors:  Celine C Berthier; Matthias Kretzler; Anne Davidson
Journal:  Clin Immunol       Date:  2016-08-14       Impact factor: 3.969

Review 6.  Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF-α treatment? Case report and literature review.

Authors:  Savvas Psarelis; Andreas P D Hajineocli; Eleni Hadjicosta; Hugh St A Elliott; Paul Johnson
Journal:  Clin Rheumatol       Date:  2017-02-23       Impact factor: 2.980

7.  The IL-23/IL-17 axis promotes the formation of retinal neovascularization by activating the NLRP3 inflammasome in macrophages in an experimental retinopathy mouse model.

Authors:  Ailing Sui; Xiuping Chen; Yiyun Yao; Yixuan Yao; Xi Shen; Yanji Zhu; Bing Xie
Journal:  Immunology       Date:  2021-08-30       Impact factor: 7.397

8.  IL-17 and immunologically induced senescence regulate response to injury in osteoarthritis.

Authors:  Heather J Faust; Hong Zhang; Jin Han; Matthew T Wolf; Ok Hee Jeon; Kaitlyn Sadtler; Alexis N Peña; Liam Chung; David R Maestas; Ada J Tam; Drew M Pardoll; Judith Campisi; Franck Housseau; Daohong Zhou; Clifton O Bingham; Jennifer H Elisseeff
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 19.456

Review 9.  Osteoimmunology and Beyond.

Authors:  Lia Ginaldi; Massimo De Martinis
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

10.  CXCL4 is a novel inducer of human Th17 cells and correlates with IL-17 and IL-22 in psoriatic arthritis.

Authors:  Alsya J Affandi; Sandra C Silva-Cardoso; Samuel Garcia; Emmerik F A Leijten; Tessa S van Kempen; Wioleta Marut; Joel A G van Roon; Timothy R D J Radstake
Journal:  Eur J Immunol       Date:  2018-01-15       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.